Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
58
ACRS Quote, Financials, Valuation and Earnings
Last price:
$2.65
Seasonality move
:
42.41%
Day range:
$2.58 - $2.90
52-week range:
$1.05 - $3.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.48x
P/B ratio:
2.39x
Volume:
1M
Avg. volume:
1.2M
1-year change:
1.92%
Market cap:
$287.1M
Revenue:
$18.7M
EPS (TTM):
-$1.38
Analysts' Opinion
-
Consensus RatingAclaris Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.67, Aclaris Therapeutics, Inc. has an estimated upside of 189.31% from its current price of $2.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $2.65.
Fair Value
-
According to the consensus of 6 analysts, Aclaris Therapeutics, Inc. has 189.31% upside to fair value with a price target of $7.67 per share.
ACRS vs. S&P 500
-
Over the past 5 trading days, Aclaris Therapeutics, Inc. has underperformed the S&P 500 by -13.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aclaris Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aclaris Therapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Aclaris Therapeutics, Inc. reported revenues of $3.3M.
Earnings Growth
-
Aclaris Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aclaris Therapeutics, Inc. reported earnings per share of -$0.12.
Enterprise value:
193.4M
EV / Invested capital:
--
Price / LTM sales:
19.48x
EV / EBIT:
--
EV / Revenue:
12.29x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-2.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$626K
Return On Assets:
-73.37%
Net Income Margin (TTM):
-900.01%
Return On Equity:
-103.93%
Return On Invested Capital:
-102.07%
Operating Margin:
-516.79%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $21.4M | $27.1M | $15.7M | $4.3M | $3.3M | |
| Gross Profit | $17.2M | $14.5M | $626K | $1.9M | $850K | |
| Operating Income | -$106.9M | -$56.4M | -$65.6M | -$9.6M | -$17M | |
| EBITDA | -$106.1M | -$55.6M | -$64.9M | -$9.4M | -$16.8M | |
| Diluted EPS | -$1.67 | -$0.52 | -$1.38 | -$0.11 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $205.8M | $256.6M | $123.1M | $132.3M | $100.6M | |
| Total Assets | $263.5M | $267.6M | $218.4M | $182.4M | $175.5M | |
| Current Liabilities | $17.8M | $19.8M | $27.3M | $18.8M | $25.6M | |
| Total Liabilities | $46.9M | $47.8M | $62M | $52.2M | $55.4M | |
| Total Equity | $216.6M | $219.8M | $156.3M | $130.2M | $120.1M | |
| Total Debt | $3.1M | $1.6M | $1.8M | $2.2M | $1.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$90.7M | -$17.9M | -$42.9M | $22M | -$10.9M | |
| Cash From Investing | $41.4M | $26.5M | -$50.7M | $2.8M | $13.8M | |
| Cash From Financing | $26.7M | $5K | $71.3M | $22K | -$3M | |
| Free Cash Flow | -$91.7M | -$18.5M | -$79.7M | $22M | -$11M | |
ACRS
Sector
Market Cap
$287.1M
$28.1M
Price % of 52-Week High
76.26%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-36.34%
-1.55%
1-Year Price Total Return
1.92%
-19.36%
Beta (5-Year)
0.416
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.98
200-day SMA
Buy
Level
$1.86
Bollinger Bands (100)
Buy
Level
1.81 - 2.77
Chaikin Money Flow
Buy
Level
16.5M
20-day SMA
Sell
Level
$3.07
Relative Strength Index (RSI14)
Sell
Level
41.11
ADX Line
Sell
Level
31.31
Williams %R
Buy
Level
-91.3043
50-day SMA
Sell
Level
$2.70
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
204.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.4068)
Sell
CA Score
(Annual)
Level (-0.3767)
Buy
Beneish M-Score
(Annual)
Level (-4.2084)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.4699)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Stock Forecast FAQ
In the current month, ACRS has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ACRS average analyst price target in the past 3 months is $7.67.
-
Where Will Aclaris Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aclaris Therapeutics, Inc. share price will rise to $7.67 per share over the next 12 months.
-
What Do Analysts Say About Aclaris Therapeutics, Inc.?
Analysts are divided on their view about Aclaris Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aclaris Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Aclaris Therapeutics, Inc.'s Price Target?
The price target for Aclaris Therapeutics, Inc. over the next 1-year time period is forecast to be $7.67 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ACRS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aclaris Therapeutics, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACRS?
You can purchase shares of Aclaris Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aclaris Therapeutics, Inc. shares.
-
What Is The Aclaris Therapeutics, Inc. Share Price Today?
Aclaris Therapeutics, Inc. was last trading at $2.65 per share. This represents the most recent stock quote for Aclaris Therapeutics, Inc.. Yesterday, Aclaris Therapeutics, Inc. closed at $2.65 per share.
-
How To Buy Aclaris Therapeutics, Inc. Stock Online?
In order to purchase Aclaris Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ACRS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACRS
Sector
P/E ratio
--
24.09x
PEG ratio
-0.01x
-0.01x
P/B ratio
2.39x
1.83x
Price / LTM sales
19.48x
1.59x
Growth Metrics
ACRS
Sector
Revenue growth
-24.09%
4.68%
Earnings growth
-12.14%
10.88%
Revenue (5-year growth)
34.67%
6.45%
Earnings forecast
-$0.14
-$0.18
Profitability
ACRS
Sector
Profitability FY 2024
$3.5M
$3.6M
Return on invested capital
-102.07%
-31.87%
Return on assets
-73.37%
-28.18%
Return on equity
-103.93%
-37.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
ACRS
Sector
Total cash
$95.9M
$26.2M
Short term investments
$89M
$25.7M
Total assets
$220.3M
$76.7M
Long term debt
$1.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
